CLAIMS

1. Use of a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) in the manufacture of a medicament for the treatment of cancer, wherein the FGFR1 ECD is to be administered in combination with docetaxel.

2. The use according to claim 1, wherein the FGFR1 ECD is to be administered in combination with at least one additional agent selected from paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, etoposide, topotecan, a VEGF antagonist, a VEGF trap, an anti-VEGF antibody, and bevacizumab.

3. The use according to claim 1 or 2, wherein the FGFR1 ECD comprises an amino acid sequence selected from SEQ ID NOs: 1 to 4.

4. The use according to claim 1, 2 or 3, wherein the FGFR1 ECD further comprises a fusion partner.

5. The use according to claim 4, wherein the FGFR1 ECD fusion partner is an Fc.

6. The use according to claim 5, wherein the FGFR1 ECD and Fc comprise a sequence selected from SEQ ID NO: 5 and SEQ ID NO: 6.

7. A dosage pack comprising at least one component selected from: (i) a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD), (ii) a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) fusion molecule, and (iii) docetaxel, wherein the dosage pack further comprises instructions for concurrently administering an FGFR1 ECD and/or FGFR1 ECD fusion molecule and the docetaxel to a patient.

CLAIMS

1. Use of a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) in the manufacture of a medicament for the treatment of cancer, wherein the FGFR1 ECD is to be administered in combination with docetaxel, wherein the FGFR1 ECD comprises an amino acid sequence selected from SEQ ID NOs: 1 to 4, and wherein the combination results in synergistic inhibition of tumor growth in a mouse xenograft cancer model.

2. The use according to claim 1, wherein the FGFR1 ECD and docetaxel combination is to be administered in combination with at least one additional agent selected from paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, etoposide, topotecan, a VEGF antagonist, a VEGF trap, an anti-VEGF antibody, and bevacizumab.

3. The use according to claim 1 or 2, wherein the FGFR1 ECD further comprises a fusion partner.

4. The use according to claim 3, wherein the FGFR1 ECD fusion partner is an Fc.

5. The use according to claim 4, wherein the FGFR1 ECD and Fc comprise a sequence selected from SEQ ID NO:5 and SEQ ID NO:6.